Celyad Zal Update Voorstellen van CYAD-101 voor Gevorderde Colorectale Kanker en Volgende Generatie shRNA Platform bij 2020 ASCO Virtual Scientific Program

  • Twee geaccepteerde abstracts worden virtueel gepresenteerd in een vooraf opgenomen posterpresentatie

MONT-SAINT-GUIBERT, België--()--Koersgevoelige Informatie:

Celyad (Brussels:CYAD) (Paris:CYAD) (NASDAQ:CYAD) (Euronext Brussel en Parijs, en Nasdaq: CYAD), een biofarmaceutisch bedrijf in klinische fase dat zich richt op de ontwikkeling van CAR-T celtherapieën, kondigde vandaag aan dat twee abstracts zijn geaccepteerd voor posterpresentatie op het Virtual Scientific Program van de American Society for Clinical Oncology (ASCO) 2020, dat zal worden gehouden van 29 tot 31 mei 2020. De eerste poster focust op CYAD-101, het eerste in zijn klasse, niet-genetisch bewerkte, allogene CAR-T programma van het bedrijf voor de behandeling van uitgezaaide colorectale kanker, terwijl de tweede poster het volgende generatie short-hairpin RNA (shRNA) technologieplatform van het bedrijf zal belichten dat gebruikt wordt in de CYAD-200 serie van allogene CAR-T productkandidaten van het bedrijf.

Filippo Petti, de CEO van Celyad, merkte op, “Wij zijn enthousiast om een update te delen op de aanstaande jaarlijkse ASCO vergadering over onze industrie-leidende allogene CAR-T kandidaat CYAD-101 voor de behandeling van solide tumoren, en ook een belangrijke update te geven over de vooruitgang van ons volgende-generatie shRNA platform, dat toelaat in een enkel CAR-T construct de functie van meerdere genen te remmen zonder het gebruik van gen-bewerking”.

ASCO 2020 Presentatie Details

Abstract 3032:

CYAD-101: An innovative non-gene edited allogeneic CAR-T for solid tumor cancer therapy

Datum & Tijd:

Virtuele posterpresentatie beschikbaar 29-31 mei 2020

 

 

Abstract 3103:

Single vector multiplexed shRNA provides a non-gene edited strategy to concurrently knockdown the expression of multiple genes in CAR T cells

Datum & Tijd:

Virtuele posterpresentatie beschikbaar 29-31 mei 2020

De vandaag gepubliceerde samenvattingen zullen op 13 mei beschikbaar zijn op de website van ASCO. Na de presentatie op de bijeenkomst zullen de posters beschikbaar zijn op de website van Celyad.

Over CYAD-101

CYAD-101 is een niet-genetisch bewerkte, allogene (van gezonde donoren afgeleide) CAR-T therapie in onderzoeksfase, die is ontwikkeld om een chimeer antigeenreceptor (CAR) op basis van NKG2D, een receptor die zich bindt aan acht stress-geïnduceerde liganden, te co-expresseren met het nieuwe remmende peptide TIM (T-celreceptor (TCR) Inhibitory Molecule). De expressie van TIM vermindert de signalering van het TCR-complex, dat verantwoordelijk is voor graft-versus host disease (GvHD).

Over shRNA Platform en CYAD-200 Serie

Het bedrijf richt zich op de ontwikkeling van zijn eigen niet-genetisch bewerkte allogene korte haarspeld RNA (shRNA) SMARTvector technologieplatform door middel van de CYAD-200 serie van productkandidaten. Het bedrijf evalueert momenteel verschillende op shRNA gebaseerde allogene CAR-T kandidaten, waaronder CYAD-211, een allogene CAR-T therapie die gericht is op B-cel rijping antigeen (BCMA) voor de behandeling van relapsed/refractory multiple myeloma.

Over Colorectale Kanker

Colorectale kanker is de derde meest voorkomende vorm van kanker bij zowel mannen als vrouwen wereldwijd en is de vierde meest voorkomende vorm van kanker in termen van sterfte. In 2018 werden ongeveer 1,8 miljoen mensen gediagnosticeerd met darmkanker, met ongeveer 140.000 en 500.000 diagnoses in respectievelijk de Verenigde Staten en Europa. Volgens gegevens van ASCO wordt ongeveer 40% van de patiënten gediagnosticeerd met een ziekte in een vroeg stadium, een gelokaliseerde ziekte. Het vijfjarig overlevingspercentage van de gelokaliseerde ziekte is ongeveer 90%. Bij patiënten waarbij de kanker is uitgezaaid naar verre delen van het lichaam, zoals bij uitgezaaide colorectale kanker, daalt het vijfjarig overlevingspercentage tot ongeveer 15%.

About Celyad

Celyad is a clinical-stage biopharmaceutical company focused on the development of specialized CAR-T cell-based product candidates and utilizes its expertise in cell engineering to target cancer. Celyad’s CAR-T cell platform has the potential to treat a broad range of solid and hematologic tumors. The company’s lead clinical candidate, CYAD-01, an autologous NKG2D-based CAR-T therapy, is currently being evaluated in several Phase 1 clinical trials to assess safety and clinical activity for the treatment of hematological malignancies, such as acute myeloid leukemia, and solid cancers, such as metastatic colorectal cancer. Celyad is also developing CYAD-101, an investigational, non-gene edited, allogeneic (donor derived) NKG2D-based CAR-T therapy, which is currently being evaluated in a Phase 1 trial for the treatment of patients with metastatic colorectal cancer. Celyad was founded in 2007 and is based in Mont-Saint-Guibert, Belgium, and New York, NY. Celyad’s ordinary shares are listed on the Euronext Brussels and Euronext Paris exchanges, and its American Depository Shares are listed on the Nasdaq Global Market, all under the ticker symbol CYAD.

Forward-looking statements

This release may contain forward-looking statements, including statements regarding: the safety and clinical activity of CYAD-01, CYAD-02, CYAD-100 Series and CYAD-200 Series; statements regarding the ongoing and planned clinical development of CYAD-01, CYAD-02, CYAD-100 Series and CYAD-200 Series, including the timing of trials, enrolment, data readouts and presentations; the clinical and commercial potential of CYAD-01, CYAD-02, CYAD-100 Series and CYAD-200 Series; the success of the OptimAb manufacturing system; the ongoing and planned clinical and commercial potential and development of Celyad’s shRNA technology; Celyad’s financial condition, results of operation and business outlook. Forward-looking statements may involve known and unknown risks, uncertainties and other factors which might cause actual results, financial condition and liquidity, performance or achievements of Celyad, or industry results, to differ materially from those expressed or implied by such forward-looking statements. In particular it should be noted that the data summarized above are preliminary in nature. There is limited data concerning safety and clinical activity following treatment with the CYAD-01, CYAD-02, CYAD-100 Series and CYAD-200 Series product candidates. These results may not be repeated or observed in ongoing or future studies involving the CYAD-01, CYAD-02, CYAD-100 Series and CYAD-200 Series drug product candidates. These forward-looking statements are further qualified by important factors and risks, which could cause actual results to differ materially from those in the forward-looking statements, including statements about: the initiation, timing, progress and results of our preclinical studies and clinical trials, and our research and development programs; our ability to advance drug product candidates into, and successfully complete, clinical trials; our ability to successfully manufacture drug product for our clinical trials, including with our OptimAb manufacturing process and with respect to manufacturing drug product with the desired number of T cells under our clinical trial protocols; our reliance on the success of our drug product candidates, including our dependence on the regulatory approval of CYAD-01, CYAD-02, CYAD-100 Series and CYAD-200 Series in the United States and Europe and subsequent commercial success of CYAD-01, CYAD-02, CYAD-100 Series and CYAD-200 Series, both of which may never occur; the timing or likelihood of regulatory filings and approvals; our ability to develop sales and marketing capabilities; the commercialization of our drug product candidates, if approved; the pricing and reimbursement of our drug product candidates, if approved; the implementation of our business model, strategic plans for our business, drug product candidates and technology; the scope of protection we are able to establish and maintain for intellectual property rights covering our drug product candidates and technology; our ability to operate our business without infringing, misappropriating or otherwise violating the intellectual property rights and proprietary technology of third parties; cost associated with enforcing or defending intellectual property infringement, misappropriation or violation; product liability; and other claims; regulatory development in the United States, the European Union, and other jurisdictions; estimates of our expenses, future revenues, capital requirements and our needs for additional financing; the potential benefits of strategic collaboration agreements and our ability to maintain and enter into strategic arrangements; our ability to maintain and establish collaborations or obtain additional grant funding; the rate and degree of market acceptance of our drug product candidates, if approved; our financial performance; developments relating to our competitors and our industry, including competing product candidates and statements regarding future revenue, hiring plans, expenses, capital expenditures, capital requirements and share performance and the impact of the novel coronavirus, COVID-19, including potential effects on our business, clinical trials, supply chain and manufacturing capabilities. A further list and description of these risks, uncertainties and other risks can be found in Celyad’s U.S. Securities and Exchange Commission (SEC) filings and reports, including in its Annual Report on Form 20-F filed with the SEC on March 25, 2020 and subsequent filings and reports by Celyad. Given these uncertainties, the reader is advised not to place any undue reliance on such forward-looking statements. These forward-looking statements speak only as of the date of publication of this document and Celyad’s actual results may differ materially from those expressed or implied by these forward-looking statements. Celyad expressly disclaims any obligation to update any such forward-looking statements in this document to reflect any change in its expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based, unless required by law or regulation.

Contacts

Celyad
Filippo Petti, Chief Executive Officer – investors@celyad.com
Alexandrine Hazard, Communications Associate – T: +32(0) 10 39 41 58 – communications@celyad.com

U.S.: LifeSci Advisors
Investor Relations: Daniel Ferry – T.: +1 (617) 535 7746 – daniel@lifesciadvisors.com
Public Relations: Sara Zelkovic – T.: +1 (646) 876 4933 – sara@lifescicomms.com

Contacts

Celyad
Filippo Petti, Chief Executive Officer – investors@celyad.com
Alexandrine Hazard, Communications Associate – T: +32(0) 10 39 41 58 – communications@celyad.com

U.S.: LifeSci Advisors
Investor Relations: Daniel Ferry – T.: +1 (617) 535 7746 – daniel@lifesciadvisors.com
Public Relations: Sara Zelkovic – T.: +1 (646) 876 4933 – sara@lifescicomms.com